PUBLISHER: The Business Research Company | PRODUCT CODE: 1945410
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945410
Intranasal drug delivery devices are medical instruments designed to administer medications into the nasal cavity. These devices are specifically created to deliver medications directly to the highly vascularized nasal mucosa, which boasts a substantial surface area, facilitating rapid absorption of the drug into the bloodstream. Intranasal drug delivery devices are capable of delivering drugs or therapeutic substances in various forms, including sprays, powders, or liquid solutions, directly into the nasal cavity.
The primary products within the realm of intranasal drug delivery devices include powder delivery devices, liquid delivery devices, pressurized metered-dose inhalers, and other related devices. Powder delivery devices, a subtype of medical or pharmaceutical devices, are designed for administering medications in unit-dose or multi-dose forms and find applications in various medical conditions such as chronic obstructive pulmonary disease (COPD), rhinitis, cystic fibrosis, nasal congestion, asthma, among others. The end users of these devices include hospitals, clinics, homecare, and other healthcare settings.
Tariffs are impacting the intranasal drug delivery devices market by increasing costs of imported polymers, precision plastic components, metered-dose mechanisms, and pharmaceutical-grade materials used in sprays, inhalers, and nasal devices. Manufacturers in North America and Europe are particularly affected due to reliance on specialized imported components, while Asia-Pacific faces cost pressures on device exports. These tariffs are raising production costs and extending development timelines. However, they are also encouraging localized device manufacturing, regional supplier diversification, and investments in cost-optimized nasal delivery technologies.
The intranasal drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides intranasal drug delivery devices market statistics, including intranasal drug delivery devices industry global market size, regional shares, competitors with a intranasal drug delivery devices market share, detailed intranasal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal drug delivery devices industry. This intranasal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The intranasal drug delivery devices market size has grown strongly in recent years. It will grow from $65.09 billion in 2025 to $70.77 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing prevalence of respiratory and nasal disorders, rising use of nasal route for systemic drug delivery, growth in self-administration drug devices, increasing approvals of intranasal therapies, expansion of outpatient treatment models.
The intranasal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $99.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing development of biologics and vaccines via nasal delivery, rising demand for homecare drug administration, expansion of intranasal delivery for neurological therapies, growing investments in advanced drug-device combinations, increasing focus on patient compliance solutions. Major trends in the forecast period include increasing adoption of precision nasal delivery systems, rising demand for non-invasive drug administration, growing development of multi-dose nasal devices, expansion of patient-friendly drug delivery formats, enhanced focus on rapid drug absorption.
The rising prevalence of chronic diseases is anticipated to drive the growth of the intranasal drug delivery devices market in the coming years. Chronic diseases are conditions that persist for one year or longer and require continuous medical care, limit daily activities, or both. Intranasal drug delivery devices are used in the management of chronic diseases by offering a non-invasive and effective method of medication administration. These devices enable drugs to be delivered directly to the targeted area, providing convenience, ease of use, and rapid absorption. For example, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the number of individuals in England at risk of developing type 2 diabetes increased to 3,615,330 from 3,066,330 in 2022, with more than half a million additional people (549,000) identified as having non-diabetic hyperglycemia, or pre-diabetes. Therefore, the growing prevalence of chronic diseases is fueling the expansion of the intranasal drug delivery devices market.
Major pharmaceutical companies in the nasal drug delivery technology market are actively engaged in developing new and improved products to offer innovative drug administration methods and maintain their market position. For instance, in January 2023, AptarGroup, Inc., a US-based drug delivery and pharmaceutical company, introduced APF Futurity, the first recyclable, metal-free, multidose nasal spray for delivering nasal saline and similar over-the-counter (OTC) formulations. This product, made from polyolefin materials and devoid of metal components or recycling disruptors, reduces the need for separation in recycling streams and supports a higher grade of recycled materials. Notably, APF Futurity is a highly recyclable nasal spray pump that has obtained Class AA certification from cyclos-HTP for recycling streams in Europe.
In January 2024, Kindeva Drug Delivery, a US-based provider of drug-device combination product development and manufacturing, acquired Summit Biosciences Inc. for an undisclosed amount. Through this acquisition, Kindeva seeks to enhance its drug-delivery platform by incorporating specialized intranasal formulation and manufacturing capabilities, allowing it to support biopharma clients across a wider range of complex combination products. Summit Biosciences Inc. is a US-based contract development and manufacturing organization specializing in intranasal drug-delivery solutions.
Major companies operating in the intranasal drug delivery devices market are Johnson and Johnson Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group plc., OptiNoset Inc., Flamel Technologies, Aegis Therapeutics LLC, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, ENT Technologies Pty. Ltd., Neurelis Inc.
North America was the largest region in the intranasal drug delivery devices market in 2025. The regions covered in the intranasal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the intranasal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The intranasal drug delivery devices market consists of sales of nasal sprays, nasal powder devices, nasal antipsychotic medications, nasal epinephrine devices, nasal drops, and nasal inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Intranasal Drug Delivery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses intranasal drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for intranasal drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The intranasal drug delivery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.